362 related articles for article (PubMed ID: 34320250)
1. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
[TBL] [Abstract][Full Text] [Related]
2. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
Vickery BP; Vereda A; Nilsson C; du Toit G; Shreffler WG; Burks AW; Jones SM; Fernández-Rivas M; Blümchen K; O'B Hourihane J; Beyer K; Anagnostou A; Assa'ad AH; Ben-Shoshan M; Bird JA; Carr TF; Carr WW; Casale TB; Chong HJ; Ciaccio CE; Dorsey MJ; Fineman SM; Fritz SB; Greiner AN; Greos LS; Hampel FC; Ibáñez MD; Jeong DK; Johnston DT; Kachru R; Kim EH; Lanser BJ; Leonard SA; Maier MC; Mansfield LE; Muraro A; Ohayon JA; Oude Elberink JNG; Petroni DH; Pongracic JA; Portnoy JM; Rachid R; Rupp NT; Sanders GM; Sharma HP; Sharma V; Sher ER; Sher L; Sindher SB; Siri D; Spergel JM; Sprikkelman AB; Sussman GL; Tsoumani M; Varshney P; Vitalpur G; Wang J; Yang WH; Zubeldia JM; Smith A; Ryan R; Adelman DC
J Allergy Clin Immunol Pract; 2021 May; 9(5):1879-1889.e13. PubMed ID: 33359589
[TBL] [Abstract][Full Text] [Related]
3. Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.
Blumchen K; Kleinheinz A; Klimek L; Beyer K; Anagnostou A; Vogelberg C; Butovas S; Ryan R; Norval D; Zeitler S; Du Toit G
Allergy Asthma Clin Immunol; 2023 Mar; 19(1):21. PubMed ID: 36915184
[TBL] [Abstract][Full Text] [Related]
4. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A; Shreffler W; Vickery BP; Casale T; Skeel B; Adelman D
J Allergy Clin Immunol; 2022 Jun; 149(6):2043-2052.e9. PubMed ID: 34971646
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
6. Peanut (
Casale TB; Irani AM
Expert Rev Clin Immunol; 2023 Mar; 19(3):253-265. PubMed ID: 36524617
[TBL] [Abstract][Full Text] [Related]
7. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J; Scurlock AM; Vickery BP; Smith A; Tilles SA; Adelman DC; Brown KR;
Ann Allergy Asthma Immunol; 2022 Dec; 129(6):758-768.e4. PubMed ID: 35973655
[TBL] [Abstract][Full Text] [Related]
8. The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.
Yu S; Smith A; Hass S; Wu E; Chai X; Zhou J; Ayyagari R; Liu JS; Robison D; Donelson SM; Tilles S
Adv Ther; 2021 Aug; 38(8):4321-4332. PubMed ID: 34236672
[TBL] [Abstract][Full Text] [Related]
9. AR101 Oral Immunotherapy for Peanut Allergy.
; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
[TBL] [Abstract][Full Text] [Related]
11. Children and caregiver proxy quality of life from peanut oral immunotherapy trials.
Galvin AD; Vereda A; Rodríguez del Río P; Muraro A; Jones C; Ryan R; Norval D; Jobrack J; Anagnostou A; Wang J
Clin Transl Allergy; 2022 Dec; 12(12):e12213. PubMed ID: 36573312
[TBL] [Abstract][Full Text] [Related]
12. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
13. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
[TBL] [Abstract][Full Text] [Related]
14. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
[TBL] [Abstract][Full Text] [Related]
16. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
[TBL] [Abstract][Full Text] [Related]
17. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp.
Portnoy J; Shroba J; Tilles S; Romdhani H; Donelson SM; Latremouille-Viau D; Bungay R; Chen K; McCann W
Ann Allergy Asthma Immunol; 2023 May; 130(5):649-656.e4. PubMed ID: 36738781
[TBL] [Abstract][Full Text] [Related]
19. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial.
Kim EH; Bird JA; Keet CA; Virkud YV; Herlihy L; Ye P; Smeekens JM; Guo R; Yue X; Penumarti A; Qaqish B; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2024 Jan; 153(1):173-181.e10. PubMed ID: 37815782
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
